
Aptinyx APTX
Quarterly report 2023-Q1
added 05-18-2023
Aptinyx Gross Profit 2011-2026 | APTX
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.56 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.56 K | 1.56 K | 1.56 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Altimmune
ALT
|
8.18 K | $ 4.2 | -2.67 % | $ 298 M | ||
|
Aptorum Group Limited
APM
|
-104 K | $ 0.8 | 1.87 % | $ 4.36 M | ||
|
Aptevo Therapeutics
APVO
|
4.31 M | $ 7.2 | -1.64 % | $ 1.99 M | ||
|
Aquestive Therapeutics
AQST
|
32.9 M | $ 4.1 | 2.37 % | $ 356 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Arcturus Therapeutics Holdings
ARCT
|
9.54 M | $ 8.35 | 1.46 % | $ 225 M | ||
|
Ardelyx
ARDX
|
4.68 M | $ 6.37 | -2.75 % | $ 1.54 B | ||
|
argenx SE
ARGX
|
2.68 M | $ 756.71 | -1.33 % | $ 25 B | ||
|
Armata Pharmaceuticals
ARMP
|
823 K | $ 10.91 | 1.58 % | $ 394 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
147 K | $ 61.74 | -2.42 % | $ 8.26 B | ||
|
Ascendis Pharma A/S
ASND
|
625 M | $ 231.56 | -0.83 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.39 | -1.63 % | $ 8.16 B | ||
|
Atossa Therapeutics
ATOS
|
-131 K | $ 4.39 | -0.9 % | $ 553 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
-52.5 M | $ 14.14 | -0.21 % | $ 1.9 B | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Axon Enterprise
AXON
|
1.24 B | $ 570.5 | 5.18 % | $ 43.2 B | ||
|
Aytu BioScience
AYTU
|
45.8 M | $ 2.56 | -0.58 % | $ 16.1 M |